Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) does about 3.25M shares in volume on a normal day but saw 8895923 shares change hands in Monday trading. The company now has a market cap of 1.09B USD. Its current market price is $5.27, marking an increase of 18.43% compared to the previous close of $4.45. The 52 week high reached by this stock is $8.96 whilst the lowest price level in 52 weeks is $4.03.
Biocryst Pharmaceuticals Inc. (BCRX) has a 20-day trading average at $4.54 and the current price is -41.18% off the 52-week high compared with 30.77% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.93 and its 200-day simple moving average is $5.93. If we look at the stock’s price movements over the week, volatility stands at 9.11%, which decreases to 6.24% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 64.22 to suggest the stock is neutral.
The consensus objective for the share price is $14.00, suggesting that the stock has a potential upside of 62.36% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 20, 2023 when JP Morgan resumed the stock to “Overweight” and issued a price target of $10. RBC Capital Mkts upgraded the stock to “Outperform” from Sector Perform on September 18, 2023 at a price target of $9-$10. Jefferies upgraded its price target at $11.
Biocryst Pharmaceuticals Inc. (BCRX) stock is up 23.42% over the week and 14.57% over the past month. Its price is -12.02% year-to-date and -37.78% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -0.28 above consensus estimates by 0.02. The company’s next earnings report forecasts estimating quarterly EPS at -0.21 and -0.63 for whole year. Expected sales for next quarter are $97.98M, which analysts say will come at $394.54M for the current fiscal year and next year at $473.7M. In addition, estimates put the company’s current quarterly revenue at an average of $85.6M.
To reach the target analysts have set, the stock logically needs to grow 62.36 percent from here.
The company has a return on investment of -61.73%. The beta has a value of 1.77. Price to sales ratio is 3.28.
